Inside Gilead Sciences: Leading in virology while diversifying into oncology and inflammation

Gilead Sciences is a biopharmaceutical company discovering and commercializing medicines in virology, oncology, and inflammation.

The company relies on strong commercial execution to deliver life-saving therapies to patients.

Leadership is focused on expanding its core HIV franchise with long-acting options while rapidly diversifying its revenue base through late-stage oncology launches.

Gilead differentiates itself through rigorous lifecycle management and standard-of-care efficacy.

Its portfolio includes Biktarvy for HIV treatment and Yeztugo, a transformative twice-yearly injectable for HIV prevention. In oncology, its Kite division leverages unparalleled cell therapy manufacturing speed and reliability, while the company moves Trodelvy into earlier lines of breast cancer treatment.CEO Daniel O'Day emphasizes a secure foundation for growth, noting no major patent losses until 2036.

Chief Commercial Officer Johanna Mercier is prioritizing the aggressive rollout of Yeztugo, targeting $800 million in 2026 revenue after achieving over 90% payer coverage.

All sourced directly from Gilead Sciences' own leadership from earnings calls and analyst briefings.